Risperidone News and Research

RSS
Young investigators to receive Brain & Behavior Research Foundation awards

Young investigators to receive Brain & Behavior Research Foundation awards

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Risperidone recall by J&J

Risperidone recall by J&J

Study: Early intervention can reduce recurrences, prevent psychosis

Study: Early intervention can reduce recurrences, prevent psychosis

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

More studies needed to identify which specific autism treatments are helpful for specific children

More studies needed to identify which specific autism treatments are helpful for specific children

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Children with ASDs benefit from certain medical and behavioral treatments

Children with ASDs benefit from certain medical and behavioral treatments

EDT receives European approval for XEPLION injection to treat schizophrenia

EDT receives European approval for XEPLION injection to treat schizophrenia

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene collaborates with Medco Health Solutions to conduct REST study

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Psychotropic medications common among children with ASD: Research

Psychotropic medications common among children with ASD: Research

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks: Ten most significant autism research achievements in 2009

New Tel Aviv University study shows early intervention could prevent mind altering disorder

New Tel Aviv University study shows early intervention could prevent mind altering disorder

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.